Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas

New England Journal of Medicine

Volumn 350, Issue 13, 2004, Pages 1328-1337

  Thorley Lawson, David A ^a   Gross, Andrew ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; BLAST CELL; BURKITT LYMPHOMA; CELL DIFFERENTIATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; INFECTIOUS MONONUCLEOSIS; LEIOMYOSARCOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; PATHOGENICITY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

B-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA; T-LYMPHOCYTES;

EID: 1642334164     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra032015     Document Type: Review

References (75)

1. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:2511-73.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:2575-627.
3. Thorley-Lawson DA. Epstein-Barr virus. In: Austen KF, Frank MM, Atkinson JP, Cantor H, eds. Sampler's immunologic diseases. 6th ed. Vol. 2. Philadelphia: Williams & Wilkins, 2001:970-85.
4. Thorley-Lawson DA, Babcock GJ. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci 1999;65:1433-53.
5. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
6. Khanna R, Slade RW, Poulsen L, et al. Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol 1997;71:8340-6.
7. Diehl V, Henle G, Henle W, Kohn G. Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol 1968;2:663-9.
8. Pope JH, Home MK, Scott W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 1968;3:857-66.
9. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998;9:395-404.
10. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Idendfication of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 1997;71:4882-91. [Erratum, J Virol 1998;72:9419.]
11. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Idendfication of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 1997;71:4882-91. [Erratum, J Virol 1998;72:9419.]
12. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 2004;101:239-44.
13. Babcock GJ, Hochberg D, Thorley-Lawson DA. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000;13:497-506.
14. Joseph AM, Babcock GJ, Thorley-Lawson DA. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 2000;74:9964-71.
15. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999;190:567-76.
16. Henle W, Henle G. Seroepidemiology of the virus. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin, Germany: Springer-Verlag, 1979:61-78.
17. Joncas J, Boucher J, Granger-Julien M, Filion C. Epstein-Barr virus infection in the neonatal period and in childhood. Can Med Assoc J 1974;110:33-7.
18. Niederman JC, McCollum RW, Henle G, Henle W. Infectious mononucleosis: clinical manifestations in relation to EB virus antibodies. JAMA 1968;203:205-9.
19. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms peripheral memory B cell compartment with resting, latently infected cells. J Virol (in press).
20. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-202.
21. Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997;156:111-26.
22. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12:117-39.
23. MacLennan IC, Liu YL, Ling NR. B cell proliferation in follicles, germinal centre formation and the site of neoplastic transformation in Burkitt's lymphoma. Curr Top Microbiol Immunol 1988;141:138-48.
24. Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Bar virus. J Immunol 1985;134:3007-12.
25. Thorley-Lawson DA, Schooley RT, Bhar AK, Nadler LM. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell 1982;30:415-25.
26. Nilsson K. The nature of lymphoid cell lines and their relationship to the virus. In Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin, Germany: Springer-Verlag, 1979:225-81.
27. Babcock GJ, Thorley-Lawson DA. Tonsilla memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A 2000;97:12250-5.
28. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998;17:1700-9.
29. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998;9:405-11.
30. Casola S, Otipoby KL, Alimzhanov M, et al. B ceU receptor signal strength determines B cell fate. Nat Immunol 2004;5:317-27.
31. Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley-Lawson DA. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 2002;16:745-54.
32. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985;313:812-5.
33. Pearson G, Dewey F, Klein G, Henle G, Henle W. Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens induced by the virus. J Natl Cancer Inst 1970;45:989-95.
34. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999;170:49-64.
35. Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-402.
36. Wood TA, Frenkel EP. The atypical lymphocyte. Am J Med 1967;42:923-36.
37. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-9.
38. Webster RG, Laver WG, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. Nature 1982;296:115-21.
39. Kurth J, Hansmann ML, Rajewsky K, Kuppers R. Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci U S A 2003;100:4730-5.
40. Kurth J, Spieker T, Wustrow J, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 2000;13:485-95.
41. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999;286:300-3.
42. Fahraeus R, Jansson A, Ricksten A, Sjoblom A, Rymo L. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A 1990;87:7390-4.
43. Wang F, Tsang SF, Kurilla MG, Cohen JL, Kieff E. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 1990;64:3407-16.
44. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003;9:307-14. [Erratum, Nat Med 2003;9:477.]
45. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003;9:307-14. [Erratum, Nat Med 2003;9:477.]
46. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002;8:594-9.
47. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92.
48. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001;356:461-73.
49. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol 2000;165:2975-81.
50. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol 2000;53:248-54.
51. Thomas JA, Hotchin NA, Allday MJ, et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990;49:944-53.
52. Timms JM, Bell A, Flavell JR, et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003;361:217-23.
53. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latency and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995;85:744-50.
54. Weiss LM, Movahed LA, Wamke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-6.
55. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70:375-82.
56. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003;349:1324-32.
57. Oudejans JJ, Dukers DF, Jiwa NM, et al. Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J Clin Pathol 1996;49:897-902.
58. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993;177:339-49.
59. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A 1991;88:4766-70.
60. Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997;90:1664-72.
61. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998;16:471-93.
62. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000;191:207-12.
63. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-3.
64. Klein G. Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell 1983;32:311-5.
65. Leder P. Translocations among antibody genes in human cancer. In: Lenoir GM, O'Conor GT, Olweny CLM, eds. Burkitt's lymphoma: a human cancer model. Lyons, France: International Agency for Research on Cancer, 1985:341-71. (IARC publications no. 60.)
66. Manolov G, Manolova Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 1972;237:33-4.
67. Klein U, Klein G, Ehlin-Henriksson B, Rajewsky K, Kuppers R, Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes. Mol Med 1995;1:495-505.
68. Gregory CD, Tursz T, Edwards CF, et al. Idendfication of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol 1987;139:313-8.
69. de-Thé G. Epstein-Barr virus and Burkitt's lymphoma worldwide: the causal relationship revisited. In: Lenoir GM, O'Conor GT, Olweny CLM, eds. Burkitt's lymphoma: a human cancer model. Lyons, France: International Agency for Research on Cancer, 1985:165-76. (IARC publications no. 60.)
70. Gulley ML, Raphael M, Lutz CT, Ross DW, Raab-Traub N. Epstein-Barr virus integration in human lymphomas and lymphoid cell lines. Cancer 1992;70:185-91.
71. Lenoir GM, Bornkamm GW. Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: proposal for a new scenario. In: Klein G, ed. Advances in viral oncology. Vol. 7. New York: Raven Press, 1987:173-206.
72. Klein G. In defense of the "old" Burkitt lymphoma scenario. In: Klein G, ed. Advances in viral oncology. Vol. 7. New York: Raven Press, 1987:207-11.
73. Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 2002;8:1098-104.
74. Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 1990;71:1481-95.
75. Polack A, Hortnagel K, Pajic A, et al. c-myc Activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci U S A 1996;93:10411-6.